Achieve Life Sciences, Inc.
corporate_fare Company Profile
Achieve Life Sciences, Inc. (NASDAQ:ACHV) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 22 items for ACHV at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-10, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 15 rated 8 or above. Recent SEC coverage for ACHV spans 10-Q, 8-K, DEF 14A, PRE 14A.
Recent high-impact activity:
- AchieveRx Q3 10-Q: $97.0M Nine-Month Loss, $201.5M Cash, NDA Resubmission Set for Q4
- AchieveRx Posts Q3 2026 Results: $201.5M Cash, NDA Resubmission on Track for Q4
- Achieve Life Sciences Q2 2026: $74.8M Loss, CRL Delays Cytisinicline Approval, Cash Runway Extended
- Achieve Life Sciences Q2 2026: $74.8M Net Loss, $187.3M Cash, and NDA Resubmission Set for Q4 2026
- Achieve Life Sciences Closes $354M Private Placement, Eyes FDA Approval in H1 2027
Financial Snapshot
Short Interest & Short Volume
13.58 days to coverFINRA reported short interest of 18,131,905 shares in ACHV as of the October 30, 2026 settlement, a 1.8% increase from the prior period — about 13.6 days to cover at its recent average daily volume.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Moderate riskFiling-implied dilution signals for ACHV, detected from its recent SEC filings.
ATM Program Established · Use of Proceeds
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →